Direct factor Xa (FXa) inhibitors (rivaroxaban, apixaban, edoxaban, and betrixaban) have become the most widely utilized class of anticoagulants in the United States. Due to their expertise in managing anticoagulation and their role as the drug information experts, pharmacists are critically important in assuring the correct FXa inhibitor is being used in the correct indication, at the correct dose, with detailed patient education to maximize positive patient outcomes. They must also be able to recognize and manage bleeds that are associated with FXa inhibitors and provide guidance on when a reversal strategy may be necessary. This activity will provide pharmacists answers to the top questions they’ll be asked by fellow clinicians about reversal of FXa inhibitors and how to safely resume anticoagulation after a bleeding event.
Credits: 1.0 hours (0.10 ceu)